A real-world clinicogenomic study of androgen receptor mutations and co-mutations in prostate cancer: Clinical implications. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers ...

Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma A total of 121 patients (previous ICI-treated cohort, n = 31, and each of ...

S2,3PSA% as a predictor of reclassification of 1st protocol biopsy on active surveillance for early-stage prostate cancer patients: From the PRIAS-JAPAN study. The nature of progression on long term ...

Burnout in oncologists has been increasing, especially after the COVID-19 pandemic. This is concerning because burnout can have both personal and professional repercussions, as well as a negative ...

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO ...

Metastasis-directed therapy (MDT) plus androgen deprivation therapy (ADT) for oligometastatic prostate cancer (omPC): Primary results of the EXTEND continuous ADT (cADT) basket plus combined analysis ...

TP53 Y220C mutations in advanced urothelial bladder cancer (UBC): A genomic landscape study. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This abstract does not ...

The improvement in measures of well-being over the past decade illustrates that progress is possible and should encourage the cancer care community to continue efforts to optimize oncology training.

Real world evidence from a retrospective multi-center analysis on first-line therapy for metastatic renal cell carcinoma with chromophobe histology.

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

Evaluating cost-effectiveness in the evolving treatment landscape for metastatic urothelial carcinoma.

If We Build It, Why They Do Not Come? An American College of Surgeons National Quality Improvement Collaborative to Understand Barriers to Completion of Cancer Treatment Study population consisted of ...